Team approach to polypharmacy evaluation and reduction: feasibility randomized trial of a structured clinical pathway to reduce polypharmacy

Table 9 Number of medication changes in intervention arm patients (n = 18) during the 6-month study period

Medication change	Prescribed n (%)	Prescribable n (%)	Non-prescribable n (%)
Medications stopped^a	11 (61)	6 (33)	4 (22)
Medications started^b	7 (39)	1 (6)	1 (6)
Medications switched^c	5 (28)	0 (0)	0 (0)
Medications with dose reduction^d	5 (28)	1 (6)	0 (0)
Medications with dose increase^e	9 (50)	0 (0)	0 (0)
Medications failed taper^f	6 (33)	0 (0)	1 (6)

^aA medication was discontinued
^bA new medication was started
^cA medication was switched to a different medication, considered to be safer, as a direct result of TAPER
^dA medication was reduced in dose or frequency of administration
^eA medication was increased in dose or frequency of administration
^fA medication was “paused and monitored” but restarted within the 6-month study period due to reoccurrence of symptoms or otherwise clinically indicated

ISSN: 2055-5784